Full Breakdown
Moderna-Merck Personalized Melanoma Vaccine Shows 42% Recurrence Reduction Amid Market Turbulence
By Drooid · · How we work
Core Findings from the Phase 3 INTerpath-001 Trial
The late-stage INTerpath-001 study evaluated the individualized mRNA vaccine intismeran autogene with Merck’s PD-1 inhibitor Keytruda versus Keytruda alone in patients whose high-risk melanoma had been surgically removed. The trial enrolled 1,137 participants (stage IIB-IV) and randomized them 2:1 to the combination or to Keytruda plus placebo. After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42 % (HR 0.58) and lowered the risk of distant metastasis or death by 38 % (HR 0.62). At two years, 82 % of patients receiving intismeran + Keytruda were alive without melanoma returning, compared with 70 % on Keytruda alone.
Background & Context
The vaccine uses the same messenger-RNA platform that enabled rapid COVID-19 vaccines, but tailors the sequence to each patient’s tumor neoantigens. Phase 2b data presented in 2026 showed a 49 % reduction in recurrence risk, setting high expectations for the Phase 3 readout. Moderna and Merck announced in August that the trial met its primary endpoint, with detailed results released at the European Society for Medical Oncology (ESMO) Congress in Madrid.
Data & Statistics
| Metric | Combination | Keytruda alone |
|---|---|---|
| Recurrence-free survival at 2 yr | 82 % | 70 % |
| Distant-metastasis-free survival at 2 yr | 88.5 % | 80 % |
| Relative risk reduction (recurrence) | 42 % (HR 0.58) | — |
| Relative risk reduction (metastasis) | 38 % (HR 0.62) | — |
| Trial size | 1,137 (2:1) | — |
| Median follow-up | 24.6 mo | — |
| Discontinuations (adverse events) | 7 % | 5 % |
Official Statements & Responses
Moderna and Merck released the data after a brief online leak on October 22 and noted that overall-survival data remain immature but show a “favorable trend.” ESMO lifted its embargo, highlighting the significance of a personalized vaccine achieving a practice-changing efficacy signal in the adjuvant melanoma setting. Analysts at BMO Capital Markets called the 42 % reduction “clinically meaningful,” while UBS described the dataset as “strong.”
On-the-Ground Reports
Patients reported typical vaccine-related side effects, most notably transient fever and injection-site pain. Ted Komenda, a 55-year-old participant from Boston, said he experienced flu-like symptoms after each dose and, after two years of monitoring, has seen no signs of melanoma recurrence.
Conflicting Reports & Gaps
The efficacy numbers exceeded many analysts’ projected 40-50 % recurrence-risk reduction, yet the market reacted with a sharp sell-off, wiping roughly $24 billion from Moderna’s market value. Long-term overall-survival outcomes and performance in other tumor types remain unanswered, leaving investors and clinicians awaiting the full ESMO presentation scheduled for October 24.
What’s Next
The full INTerpath-001 results will be presented at the ESMO Congress on October 24. Moderna and Merck have ongoing Phase 2/3 trials of intismeran in non-small cell lung cancer, bladder cancer, and renal cell carcinoma, with interim kidney-cancer data expected later this year or early 2027. Regulatory discussions with the FDA and EMA are underway, and both companies will engage with authorities as additional data mature.